# BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

> **NCT04932863** · — · COMPLETED · sponsor: **Ente Ospedaliero Ospedali Galliera** · enrollment: 300 (actual)

## Conditions studied

- Neoplasms
- Cancer, Treatment-Related

## Interventions

- **BIOLOGICAL:** BNT162b2 mRNA Covid-19 Vaccine

## Key facts

- **NCT ID:** NCT04932863
- **Lead sponsor:** Ente Ospedaliero Ospedali Galliera
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2022-03-15
- **Final completion:** 2023-03-15
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04932863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04932863, "BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04932863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*